Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

• Status: Recruiting
• Trial end date: 2028-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sacramento Pediatric Gastroenterology
• Treatments: Vancomycin

Criteria

Inclusion Criteria:

• Persons who have primary sclerosing cholangitis, biliary atresia, a chronic intestinal disorder or who are undergoing upper or lower endoscopy.

• Persons who have primary sclerosing cholangitis or biliary atresia who are good candidates for vancomycin therapy.

Exclusion Criteria:

• Patients that have taken antibiotics and/or immunomodulators within the last 3 months will be excluded as this will alter the original bacterial flora.

• Females who are pregnant may not participate.